SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SANGAMO THERAPEUTICS, INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
SANGAMO THERAPEUTICS, INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 18 | TTM Q4 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | – | – | – | – | – | – | $84.07M | $35.96M | – | – |
| Research grants | – | – | – | – | – | – | $387.00K | $607.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Sangamo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.